RVL Pharmaceuticals plc O1P.F Stock
RVL Pharmaceuticals plc Price Chart
RVL Pharmaceuticals plc O1P.F Financial and Trading Overview
| RVL Pharmaceuticals plc stock price | 0.0030 EUR |
| Previous Close | 0.74 EUR |
| Open | 0.76 EUR |
| Bid | 0.77 EUR x 0 |
| Ask | 0.8 EUR x 0 |
| Day's Range | 0.76 - 0.76 EUR |
| 52 Week Range | 0.69 - 2.9 EUR |
| Volume | 1.08K EUR |
| Avg. Volume | 0 EUR |
| Market Cap | 75.77M EUR |
| Beta (5Y Monthly) | 1.088701 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.67 EUR |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 6.5 EUR |
O1P.F Valuation Measures
| Enterprise Value | 100.12M EUR |
| Trailing P/E | N/A |
| Forward P/E | -1.2583333 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | 2.0417898 |
| Price/Book (mrq) | 1.8734491 |
| Enterprise Value/Revenue | 2.698 |
| Enterprise Value/EBITDA | -2.25 |
Trading Information
RVL Pharmaceuticals plc Stock Price History
| Beta (5Y Monthly) | 1.088701 |
| 52-Week Change | -33.18% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 2.9 EUR |
| 52 Week Low | 0.69 EUR |
| 50-Day Moving Average | 0.84 EUR |
| 200-Day Moving Average | 1.35 EUR |
O1P.F Share Statistics
| Avg. Volume (3 month) | 0 EUR |
| Avg. Daily Volume (10-Days) | 0 EUR |
| Shares Outstanding | 99.35M |
| Float | 34.08M |
| Short Ratio | N/A |
| % Held by Insiders | 27.03% |
| % Held by Institutions | 49.26% |
| Shares Short | N/A |
| Short % of Float | N/A |
| Short % of Shares Outstanding | N/A |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2022 |
| Most Recent Quarter (mrq) | March 31, 2023 |
| Next Fiscal Year End | December 31, 2023 |
Profitability
| Profit Margin | -152.20% |
| Operating Margin (ttm) | -120.92% |
| Gross Margin | 81.64% |
| EBITDA Margin | -119.90% |
Management Effectiveness
| Return on Assets (ttm) | -21.96% |
| Return on Equity (ttm) | -103.18% |
Income Statement
| Revenue (ttm) | 37.11M EUR |
| Revenue Per Share (ttm) | 0.4 EUR |
| Quarterly Revenue Growth (yoy) | -58.79% |
| Gross Profit (ttm) | 43.07M EUR |
| EBITDA | -44496000 EUR |
| Net Income Avi to Common (ttm) | -56483000 EUR |
| Diluted EPS (ttm) | -0.56 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 32.64M EUR |
| Total Cash Per Share (mrq) | 0.33 EUR |
| Total Debt (mrq) | 57.75M EUR |
| Total Debt/Equity (mrq) | 144.38 EUR |
| Current Ratio (mrq) | 2.337 |
| Book Value Per Share (mrq) | 0.403 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -30352000 EUR |
| Levered Free Cash Flow (ttm) | -5449250 EUR |
Profile of RVL Pharmaceuticals plc
| Country | Germany |
| State | NJ |
| City | Bridgewater |
| Address | 400 Crossing Boulevard |
| ZIP | 08807 |
| Phone | 908 809 1300 |
| Website | https://www.rvlpharma.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 125 |
RVL Pharmaceuticals plc, a specialty pharmaceutical company, focuses on the development and commercialization of pharmaceutical products that target markets with underserved patient populations in the ocular and medical aesthetics therapeutic areas in the United States, Argentina, and Hungary. It is commercializing Upneeq (RVL-1201), an oxymetazoline hydrochloride ophthalmic solution, for the treatment of acquired blepharoptosis, or low-lying eyelid in adults. The company was formerly known as Osmotica Pharmaceuticals plc and changed its name to RVL Pharmaceuticals plc in January 2022. RVL Pharmaceuticals plc is headquartered in Bridgewater, New Jersey.
Q&A For RVL Pharmaceuticals plc Stock
What is a current O1P.F stock price?
RVL Pharmaceuticals plc O1P.F stock price today per share is 0.0030 EUR.
How to purchase RVL Pharmaceuticals plc stock?
You can buy O1P.F shares on the Frankfurt exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for RVL Pharmaceuticals plc?
The stock symbol or ticker of RVL Pharmaceuticals plc is O1P.F.
Which industry does the RVL Pharmaceuticals plc company belong to?
The RVL Pharmaceuticals plc industry is Biotechnology.
How many shares does RVL Pharmaceuticals plc have in circulation?
The max supply of RVL Pharmaceuticals plc shares is 631.91M.
What is RVL Pharmaceuticals plc Price to Earnings Ratio (PE Ratio)?
RVL Pharmaceuticals plc PE Ratio is now.
What was RVL Pharmaceuticals plc earnings per share over the trailing 12 months (TTM)?
RVL Pharmaceuticals plc EPS is -0.67 EUR over the trailing 12 months.
Which sector does the RVL Pharmaceuticals plc company belong to?
The RVL Pharmaceuticals plc sector is Healthcare.